Clinical Trial Update: Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

View source ↗

Summary

A completed clinical trial evaluating real-world outcomes of lorlatinib after alectinib in ALK-positive non-small-cell lung cancer patients in Japan with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)
• lorlatinib (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: ALK-positive Non-small-cell Lung Cancer | Status: COMPLETED | Results posted: 2024-04-05